Wow, after waiting 25 plus years for a gene therapy product for the hemophilia community, it never occurred to me that Biomarin’s product would be rejected by the FDA last week with a call for additional data on the durability of their product.

Our advocacy this week reminds me of a few things worth remembering.

Fighting Back

Coronavirus Update

· 2020 Outlook
· Marketing and Operating Strategic Plan Goals for 2020
· 2020 Payer Team Goals
· 2020 Advocacy and Policy Goals

Back to the Future